PATIENT GROUP SUBMISSIONS to BC PharmaCare, CADTH, & PMPRB

Whenever we are asked to contribute a patient group submission about a hepatitis-C or hepatitis-B related product, we do so. We contribute as a patient group to reviews by both BC PharmaCare (to determine whether BC PharmaCare patients will be reimbursed for the drugs) and CADTH (federal level – to determine whether the drugs will be available in Canada). Occasionally we also submit patient group input to the Patented Medicines Prices Review Board (PMPRB). Below are the submissions we have made, from the most current down to the very earliest (May, 2011).

We will continue to post to this list whenever we have another review to add. Please feel free to comment, and we hope you will help us by sending your input for each review – it really is an excellent way of helping yourself and others gain access to the best therapies for hepatitis C and hepatitis B and their complications.

2020

Patented Medicine Prices Review Board (PMPRB) Guidelines – Proposed Revisions – HepCBC Comments – February 14, 2020
https://www.canada.ca/content/dam/pmprb-cepmb/documents/consultations/draft-guidelines/submission-received/2020_02_Guideline%20Consultation%20Submission_HepCBC.pdf

Vemlidy™ (tenofovir alefenamide) – HBV – Canada
http://hepcbc.bchep.org/wp-content/uploads/2017/10/20171020_tenofovir_alafenamide_
VEMLIDY_CADTH_redact.pdf

2016

Comments from CADTH re: HepCBC’s Epclusa submission of October 26, 2016
http://hepcbc.bchep.org/wp-content/uploads/2016/12/20161221_CADTH_feedback_to_HepCBC_re_EPCLUSA.pdf

Patented Medicine Prices Review Board (PMPRB) Guidelines Modernization: Discussion Paper – HepCBC Comments – October 30, 2016
http://hepcbc.bchep.org/wp-content/uploads/2016/10/20161030_PMPRB_Critique_HepCBC_FINAL.pdf

Epclusa® (sofosbuvir + velpatasvir) – BC
http://hepcbc.bchep.org/wp-content/uploads/2016/09/BCPharmaCareEpclusa_REDACTED_20160921.pdf

asunaprevir (Sunvepra™) – BC
http://hepcbc.bchep.org/wp-content/uploads/2016/09/20160614_asunaprevir_
SUNVEPRA_PharmaCare_redact.pdf

Comments from CADTH re: HepCBC’s asunaprevir submission of March 10, 2015
http://hepcbc.bchep.org/wp-content/uploads/2016/09/20160810_CADTH_
feedback_to_HepCBC_re_asunaprevir.pdf

grazoprevir /elbasvir (Zepatier) – BC
http://hepcbc.bchep.org/wp-content/uploads/2016/05/20160420_grazoprevir_
elbasvir_ZEPATIER_PharmaCare_redact.pdf

sofosbuvir (Sovaldi) in combination with Velpatasvir – UPDATED REVIEW – Canada
http://hepcbc.bchep.org/wp-content/uploads/2016/05/20160512_sofosbuvir_velpatasvir_CADTH_redact.pdf

sofosbuvir (Sovaldi) – UPDATED REVIEW – Canada
20160223_sofosbuvir_SOVALDI_update_CADTH_redact

ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (Holkira Pak) – UPDATED REVIEW – Canada
20160223_ombitasvir_paritaprevir_ritonavir_dasabuvir_HOLKIRAPAK
_update_CADTH_redact

ledipasvir/sofosbuvir (Harvoni) – UPDATED REVIEW – Canada
20160223_ledipasvir_sofosbuvir_etc_HARVONI_update_CADTH_redact

daclatasvir (Daklinza) – UPDATED REVIEW – Canada
20160223_daclatasvir_DAKLINZA_update_CADTH_redact

ombitasvir/paritaprevir/ritonavir/ ± ribavirin (Technivie) – BC
20160216_ombitasvir_paritaprevir_ritonavir_TECHNIVIE_PharmaCare_redact

ribavirin (Ibavyr or Moderiba) Patient Attitudes Special Review – Canada
20160215_Patient_Attitudes_ribavirin_IBAVYR_or_MODERIBA_CADTH_redact

Feedback on Included Studies List on Screening HCV Review/MetaAnalysis – Canada
20160128_feedback_included_studies_screeningHCV_review_metaanalysis_redact

 

2015

grazoprevir /elbasvir (Zepatier) – Canada
20151111_grazoprevir_elbasvir_ZEPATIER_CADTH_redact

ombitasvir/paritaprevir/ritonavir ± ribavirin (Technivie) – Canada
20150928_ombitasvir_paritaprevir_ritonavir_CADTH_redact

Further CADTH questions/HepCBC answers re: HCV Part 2 Therapeutic Review – Canada
20150826_Further_Answers_for_CDEC_CADTH

daclatasvir (Daklinza) – BC
20150819_daclatasvir_DAKLINZA_PharmaCare_redact

Comments from CADTH re: HepCBC’s rifamaxin and eltrombopag submissions of August, 2014
20150602_CADTH_feedback_to_HepCBC_Re_Revolade_and_Zaxine

ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin (Holkira Pak) – BC
20150520_HolkiraPak_Pharmacare_redact

HCV Part 2 Therapeutic Review – Canada
20150317_Part2TherapeuticReview_CADTH_redact

daclatasvir (Daklinza) – Canada
20150310_daclatasvir_DAKLINZA_CADTH_redact

asunaprevir (Sunvepra) – Canada
20150310_asunaprevir_SUNPREVA_CADTH_redact

eltrombopag (Revolade) – BC
20150218_eltrombopag_REVOLADE_Pharmacare_redact

HCV Part 2 Therapeutic Review SCOPE Comments – Canada
20150213_HepCBC_Comments_CADTH_TherapeuticReviewSCOPE

rifaxamin (Zaxine)- BC
20150118_rifaxamin_ZAXINE_Pharmacare_redact

 

2014

ombitasvir, paritaprevir, ritonavir, and dasabuvir (Holkira Pak) – Canada
20141221_ombitasvir_paritaprevir_ritonavir_dasabuvir_CADTH_redact

ledipasvir and sofosbuvir (Harvoni) – Canada
20141008_ledipasvir_sofosbuvir_HARVONI_CADTH_redact

eltrombopag (Revolade) – Canada
20140829_eltrombopag_REVOLADE_CADTH_redact

rifaximin (Zaxine) – Canada (revision added Jan. 12, 2015  on request of CADTH)
20140828_REV20150112_rifaximin_ZAXINE_CADTH_redact

HCV Genotype 1 Therapeutic Review – Canada
20140826_HCV_GT1_TherapeuticReview_CADTH

sofosbuvir (Sovaldi) – BC
20140711_sofosbuvir_SOVALDI_Pharmacare_redact

simeprevir (Galexos) – BC
20140530_simeprevir_GALEXOS_PharmaCare_redact

 

2013

sofosbuvir (Sovaldi) – Canada
20131023_sofosbuvir_SOVALDI_CADTH_redact

simeprevir (Galexos) – Canada
20130913_simeprevir_GALEXOS_CADTH_redact

 

2012

telaprevir (Incivek) – BC
20120308_telaprevir _INCIVEK_PharmaCare_redact

 

2011

boceprevir (Victrelis) – BC
20111130_boceprevir_VICTRELIS_PharmaCare_redact

telaprevir (Incivek) – Canada
20110914_telaprevir_INCIVEK_CADTH_redact

boceprevir (Victrelis) – Canada
20110526_boceprevir_VICTRELIS_CADTH_redact